Gamida Cell ⚠ Under review

About

Funding history · 16 rounds · $283.0M total

Headcount over time

Q&A

What is Gamida Cell's primary focus?

Gamida Cell is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer and rare, serious hematologic diseases. They utilize a proprietary nicotinamide (NAM)-based cell expansion technology.

What is Gamida Cell's lead product and its approval status?

Gamida Cell's lead product is Omisirge (omidubicel-onlv), an FDA-approved allogeneic cell therapy for patients with blood cancers undergoing stem cell transplantation.

When was Gamida Cell acquired and by whom?

Gamida Cell was acquired by Highbridge Capital Management in May 2024 and now operates as a wholly owned subsidiary of Ayrmid Limited.

What was the most recent funding event for Gamida Cell before its acquisition?

In May 2024, Gamida Cell received $30,000,000 in Debt Financing from Highbridge Capital Management, LLC.

What was the amount of the PIPE funding round in February 2021 and who was the lead investor?

In February 2021, Gamida Cell raised $75,000,000 in a PIPE round, with.

What is the current employee count for Gamida Cell?

Gamida Cell has 93 employees, falling within the 51-200 employees bucket.

When did Gamida Cell announce the commencement of a restructuring process?

Gamida Cell announced the commencement of a restructuring process, supported by Highbridge Capital Management, in March 2024.

What was a significant product development announced in November 2024?

In November 2024, BioLineRx and Ayrmid Ltd. entered into an exclusive license agreement to commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

Sectors & technology

Highlights

Tags